StockData
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc (BDRX) stock

BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 1/30
$2.24−0.16 (-6.67%)

Close on Nov 16, 2026Market cap $5.06MP/E –Yield –

Biodexa Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Biodexa Pharmaceuticals's total debt was £61.00K at Dec 31, 2025. For fiscal 2025 it was £61.00K, down 91.6% from the year before. Over ten years it grew -29.3% a year on average. The highest annual figure on record is £6.55M in fiscal 2017.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025£61.00K-91.6%
FY2024Dec 31, 2024£727.00K+56.7%
FY2023Dec 31, 2023£464.00K-25.6%
FY2022Dec 31, 2022£624.00K-18.5%
FY2021Dec 31, 2021£766.00K+194.6%
FY2020Dec 31, 2020£260.00K-95.7%
FY2019Dec 31, 2019£6.08M+385.8%
FY2018Dec 31, 2018£1.25M-80.9%
FY2017Dec 31, 2017£6.55M+203.3%
FY2016Dec 31, 2016£2.16M+10.7%
FY2015Dec 31, 2015£1.95M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025£61.00K-88.8%
Q4 FY2024Dec 31, 2024£727.00K+16.5%
Q2 FY2024Jun 30, 2024£208.00K-72.8%
Q4 FY2023Dec 31, 2023£464.00K+78.5%
Q2 FY2023Jun 30, 2023£544.00K-91.1%
Q4 FY2022Dec 31, 2022£624.00K-50.2%
Q4 FY2021Dec 31, 2021£766.00K-88.3%
Q4 FY2020Dec 31, 2020£260.00K-88.0%
Q4 FY2019Dec 31, 2019£6.08M+211.9%
Q4 FY2018Dec 31, 2018£1.25M–
Q4 FY2017Dec 31, 2017£6.55M–
Q4 FY2016Dec 31, 2016£2.16M–
Q4 FY2015Dec 31, 2015£1.95M–

More Biodexa Pharmaceuticals figures

See a number that looks wrong?